NHF has entered Phase II of the Campaign for Our Future: Research is Our Future. This public phase gives individuals and families across the country an opportunity to support important medical research initiatives that will broaden the scope of our research agenda to assure that bleeding disorders research is a national healthcare priority.
As we reported last month, Novo Nordisk, Visionary Corporate Partner and Lead Benefactor of the Campaign for Our Future, has committed an additional $600,000 to launch the public phase of the Campaign--Research is Our Future, which will focus on advancing NHF’s research program.
To acknowledge the commitment of our supporters and to increase awareness of the importance of contributing to research, special recognition is available including a listing on our donor wall for gifts of $1,000 or more, and naming opportunities starting at $10,000.
We know that philanthropic giving is a very personal experience and we will work with you to customize giving and recognition opportunities. For more information, please contact Mary Ann Ludwig, Vice President for Development: 212.328.3741. All support, at whatever level, is welcome and appreciated. Learn more about Research is Our Future or make a contribution.
NHF acknowledges all of our 2010 Corporate Partners of the Campaign for our Future: Visionary Corporate Partner and Lead Benefactor Novo Nordisk; Principal Corporate Partner Baxter; Major Corporate Partners Bayer HealthCare, CSL Behring and Pfizer; and Corporate Partner Grifols.